Testing drug 610 in adults with severe eosinophilic asthma
Tests drug 610 against a placebo in adults with severe eosinophilic asthma.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety Study of 610 in Patients With Severe Asthma
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06323213, who can take part
Where in China
- Shanghai General HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Trial code
- NCT06323213
- Record updated
- 7 January 2026
- Original description
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 610 in Chinese Adult Subjects With Severe Eosinophilic Asthma
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
Inclusion: Able to give written informed consent prior to participation in the study; Male or female adults ages 18 to 75 years old when signing the informed consent; Documented diagnosis of asthma for at least one year prior to screening; History of physician-diagnosed asthma requiring treatment with ICS and at least one other control medication for at least 6 months prior to screening.
Exclusion: Severe asthma exacerbation within 4 weeks prior to randomization; known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment; Presence of a known pre-existing, clinically important lung condition other than asthma; Subjects with any eosinophilic diseases other than asthma; Known, pre-existing severe or clinically significant cardiovascular disease; Subjects who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening; Subjects with allergy/intolerance to a monoclonal antibody.